ArticleAmerican journal of ophthalmology2022

Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.

Gala Beykin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.